How Genexis Is Cutting Cell Culture Protein Costs By 10X With Engineered Microbes

As the Covid-19 pandemic swept across the globe with unprecedented speed and impact, countries raced to develop vaccines only to run into an unforeseen bottleneck. International trade slowed to a crawl, and global supply chains collapsed almost immediately when the virus spread. Acquiring key ingredients for vaccines became increasingly challenging, ruthlessly exposing the myth of industrial self-sufficiency. In India, the crisis was more acute. Despite its scientific capabilities and strong talent pool, the country still relied on imports for key vaccine components such as protein formulations produced by cell culture. This dependency thwarted its ambition to emerge as the world’s pharmacy and quickly turned into an urgent scramble for raw materials.

“It is a complex and fragile supply chain,” said Vipul Kumar, cofounder of Genexis Biotech. This Vadodara-based startup is part of a broader network of technology companies working to plug this gap. The cofounder then stripped back the technical complexity. Cell culture is the bedrock of biotechnology, involving the cultivation of cells in carefully controlled environments to produce vaccines and medicines. However, these cells require protein-rich nutrients for healthy growth, which are typically provided by foetal bovine serum, or FBS. The issue? FBS is obtained by collecting blood from the heart of an unborn calf, a process widely regarded as both unethical and environmentally harmful.

“We were aware of this much before the pandemic,” said Kumar. “In 2019, Dr. Jitendra Wagh and I started working on a cruelty-free protein formula that would not require animal extracts. When the pandemic shut down global supply chains and the FBS shortage delayed vaccines, it proved that we were solving a real and urgent problem.”

Genexis is now producing cell-culture proteins in India at a lower cost, without using animal extracts. It has set up an in-house facility, complete with a cleanroom to maintain strict sterility, minimizing the risk of contamination. The company has engineered microbes to produce proteins that mimic the functions of FBS, eliminating the need for animal-derived materials. This breakthrough not only addresses the ethical concerns but also reduces costs significantly.

The Genexis team has developed a proprietary process that leverages genetically modified microorganisms to produce proteins that are compatible with cell culture. These engineered microbes are designed to replicate the specific amino acids and growth factors that cells require for optimal growth. By replacing FBS with these microbial-derived proteins, Genexis has achieved a 10x reduction in production costs.

“Our technology allows for the production of high-quality proteins at a fraction of the cost,” explained Kumar. “This not only makes vaccines and medicines more affordable but also ensures a more sustainable and reliable supply chain.”

The shift from animal-derived proteins to microbial-derived alternatives is a game-changer for the biotechnology industry. Genexis’s innovation not only addresses the ethical concerns surrounding FBS but also provides a sustainable solution to the global shortage of cell culture proteins. The company’s success during the pandemic has underscored the importance of investing in innovative technologies that can mitigate supply chain disruptions.

In addition to cost savings, Genexis’s approach has environmental benefits. The production of FBS requires raising and slaughtering calves, which contributes to greenhouse gas emissions and environmental degradation. By using engineered microbes, Genexis has eliminated the need for animal-derived materials, reducing the carbon footprint of protein production.

The company’s in-house facility in Vadodara is a testament to India’s potential in the biotechnology sector. Genexis has demonstrated that with the right technology and expertise, the country can become a leader in producing essential pharmaceutical ingredients. This development is crucial for India’s ambition to reduce its dependency on imports and strengthen its position as a global player in the pharmaceutical industry.

Genexis’s innovation is expected to have a ripple effect on the biotechnology landscape. As more companies adopt microbial-derived proteins, the demand for animal-derived materials will decline, further driving down costs and promoting sustainability. The pandemic-induced disruptions have highlighted the need for alternative solutions, and Genexis’s breakthrough represents a significant step forward in addressing these challenges.

In conclusion, Genexis Biotech’s engineering of microbes to produce cell-culture proteins at a fraction of the cost of traditional methods is a groundbreaking solution to the global shortage of vaccine ingredients. The company’s innovation not only ensures a more sustainable and ethical supply chain but also positions India as a leader in the biotechnology industry. As the world continues to grapple with the aftermath of the pandemic, Genexis’s success serves as a reminder of the importance of innovation in overcoming unprecedented challenges.